⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398455 | 1.00 | — | — | |
| SCHEMBL16408283 | 0.93 | — | — | |
| SCHEMBL17791084 | 0.92 | — | — | |
| SCHEMBL29918776 | 0.91 | — | — | |
| SCHEMBL16398006 | 0.91 | — | — | |
| SCHEMBL16408240 | 0.90 | — | — | |
| SCHEMBL16398792 | 0.89 | — | — | |
| SCHEMBL16408395 | 0.87 | — | — | |
| SCHEMBL16408276 | 0.87 | — | — | |
| SCHEMBL20652608 | 0.87 | SCN8A (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122953-A1 | DOSING REGIMENS AND FORMULATIONS OF SUZETRIGINE FOR USE IN THE TREATMENT OF ACUTE AND CHRONIC PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025090465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090511-A1 | METHODS OF PREPARING MODULATORS OF SODIUM CHANNELS AND SOLID FORMS OF THE SAME FOR TREATING PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090480-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-114945566-B | Substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117858875-A | Hydroxy-and (halo) alkoxy-substituted tetrahydrofurans as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794920-A | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794537-A | Solid dosage forms and dosing regimens comprising (2 r,3s,4s,5 r) -4- [ [3- (3, 4-difluoro-2-methoxy-phenyl) -4, 5-dimethyl-5- (trifluoromethyl) tetrahydrofuran-2-carbonyl ] amino ] pyridine-2-carboxamide | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794918-A | Substituted tetrahydrofuran analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117794919-A | N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamide analogues as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-110740993-B | Deuterated pyridonamides and prodrugs thereof useful as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2023-09-01 | — | — | CN | disclosed |